BostonPremier Wealth LLC Invests $226,000 in Boston Scientific Co. (NYSE:BSX)

BostonPremier Wealth LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,528 shares of the medical equipment provider’s stock, valued at approximately $226,000.

Other institutional investors have also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter worth about $28,000. Dunhill Financial LLC increased its holdings in Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates raised its position in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in Boston Scientific in the third quarter worth approximately $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the transaction, the executive vice president now owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,830 shares of company stock worth $5,149,969. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on BSX shares. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Friday, January 10th. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, January 29th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Thursday, February 6th. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Finally, Sanford C. Bernstein boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $107.39.

Boston Scientific Price Performance

NYSE:BSX opened at $106.15 on Tuesday. The stock has a market cap of $156.44 billion, a P/E ratio of 84.92, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a one year low of $64.54 and a one year high of $107.17. The company has a fifty day moving average price of $94.88 and a 200 day moving average price of $87.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Analysts anticipate that Boston Scientific Co. will post 2.83 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.